Global pharmaceutical CDMO market will reach $289.2 billion by 2030, growing by 6.9% annually over 2020-2030 driven by increasing demand for biological therapies and specialty medicines, rising demand for cost control in drug development, and rising healthcare expenditures.
Highlighted with 96 tables and 86 figures, this 194-page report “Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Region” is based on a comprehensive research of the entire global pharmaceutical CDMO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global pharmaceutical CDMO market in every aspect of the classification from perspectives of Category, Service Type, Therapeutic Application, End User, and Region.
Based on Category, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Pharmaceutical Industry
• Biopharmaceutical Industry
Based on Service Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Pharmaceutical Contract Manufacturing Organization (CMO)
• Active Pharmaceutical Ingredients (API) (further split into Branded API Manufacturing and Generic API Manufacturing)
• Finished Dosage Formulations (FDF) (further segmented into Solid Dosage, Oral Liquids, Parenteral/Injectables, Other FDFs)
• Secondary Packaging
Pharmaceutical Contract Research Organization (CRO)
• CRO for Pre-clinical Development
• CRO for Phase I Trials
• CRO for Phase II Trials
• CRO for Phase III Trials
• CRO for Phase IV Trials
• Laboratory Services
• Consulting Services
• Data Management Services
Based on Therapeutic Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Infectious Diseases
• Oncology
• Metabolic Disorders
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Gastrointestinal Disorders
• Other Therapeutic Applications
Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Academic Institutes
Geographically, the following regions together with the listed national/local markets are fully investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Turkey, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• North America (U.S., Canada, and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (Saudi Arabia, UAE, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Category, Service Type, and Therapeutic Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in global pharmaceutical CDMO market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Company Profiles of CMO:
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH
8.3.2 Company Profiles of CRO:
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
ICON Plc
IQVIA Holdings Inc.
LSK Global Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table of Contents
1 Introduction 10
1.1 Industry Definition and Research Scope 10
1.1.1 Industry Definition 10
1.1.2 Research Scope 11
1.2 Research Methodology 14
1.2.1 Overview of Market Research Methodology 14
1.2.2 Market Assumption 15
1.2.3 Secondary Data 15
1.2.4 Primary Data 15
1.2.5 Data Filtration and Model Design 17
1.2.6 Market Size/Share Estimation 18
1.2.7 Research Limitations 19
1.3 Executive Summary 20
2 Market Overview and Dynamics 23
2.1 Market Size and Forecast 23
2.1.1 Impact of COVID-19 on World Economy 24
2.1.2 Impact of COVID-19 on the Market 27
2.2 Major Growth Drivers 29
2.3 Market Restraints and Challenges 34
2.4 Emerging Opportunities and Market Trends 37
2.5 Porter’s Fiver Forces Analysis 41
3 Segmentation of Global Market by Category 45
3.1 Market Overview by Category 45
3.2 Pharmaceutical Industry 47
3.3 Biopharmaceutical Industry 48
4 Segmentation of Global Market by Service Type 49
4.1 Market Overview by Service Type 49
4.2 Pharmaceutical Contract Manufacturing Organization (CMO) 51
4.2.1 Active Pharmaceutical Ingredients (API) 52
4.2.2 Finished Dosage Formulations (FDF) 53
4.2.3 Secondary Packaging 55
4.3 Pharmaceutical Contract Research Organization (CRO) 56
4.3.1 CRO for Pre-clinical Development 58
4.3.2 CRO for Phase I Trials 59
4.3.3 CRO for Phase II Trials 60
4.3.4 CRO for Phase III Trials 61
4.3.5 CRO for Phase IV Trials 62
4.3.6 Laboratory Services 63
4.3.7 Consulting Services 64
4.3.8 Data Management Services 65
5 Segmentation of Global Market by Therapeutic Application 66
5.1 Market Overview by Therapeutic Application 66
5.2 Infectious Diseases 68
5.3 Oncology 69
5.4 Metabolic Disorders 70
5.5 Cardiovascular Disorders 71
5.6 Central Nervous System 72
5.7 Pulmonary Disorders 73
5.8 Gastrointestinal Disorders 74
5.9 Other Therapeutic Applications 75
6 Segmentation of Global Market by End User 76
6.1 Market Overview by End User 76
6.2 Pharmaceutical & Biopharmaceutical Companies 78
6.3 Medical Device Companies 79
6.4 Academic Institutes 80
7 Segmentation of Global Market by Region 81
7.1 Geographic Market Overview 2019-2030 81
7.2 North America Market 2019-2030 by Country 85
7.2.1 Overview of North America Market 85
7.2.2 U.S. 89
7.2.3 Canada 93
7.2.4 Mexico 95
7.3 European Market 2019-2030 by Country 97
7.3.1 Overview of European Market 97
7.3.2 Germany 101
7.3.3 UK 103
7.3.4 France 105
7.3.5 Spain 107
7.3.6 Italy 109
7.3.7 Russia 111
7.3.8 Rest of European Market 113
7.4 Asia-Pacific Market 2019-2030 by Country 115
7.4.1 Overview of Asia-Pacific Market 115
7.4.2 Japan 119
7.4.3 China 122
7.4.4 Australia 124
7.4.5 India 126
7.4.6 South Korea 128
7.4.7 Rest of APAC Region 130
7.5 South America Market 2019-2030 by Country 132
7.5.1 Argentina 135
7.5.2 Brazil 137
7.5.3 Chile 139
7.5.4 Rest of South America Market 141
7.6 MEA Market 2019-2030 by Country 142
7.6.1 UAE 145
7.6.2 Saudi Arabia 147
7.6.3 South Africa 149
7.6.4 Other National Markets 151
8 Competitive Landscape 152
8.1 Overview of Key Vendors 152
8.2 New Product Launch, Partnership, Investment, and M&A 156
8.3 Company Profiles 157
8.3.1 Company Profiles of CMO 157
Aenova Group 157
Baxter BioPharma Solutions 159
Boehringer Ingelheim 160
Catalent Inc. 161
Famar S.A. 162
Hospira, Inc. 163
Jubilant Life Sciences Ltd. 164
Lonza Group 165
Patheon Inc. 166
Pfizer CentreSource 167
Recipharm AB 168
Vetter Pharma International GmbH 169
8.3.2 Company Profiles of CRO 171
Charles River Laboratories 171
CMIC Co. Ltd 173
Covance Inc. 174
Hangzhou Tigermed Consulting Co Ltd 175
ICON Plc 176
IQVIA Holdings Inc. 177
LSK Global Pharma Service Co Ltd 178
Novotech Pty Ltd 179
PAREXEL International Corporation 180
Pharmaceutical Product Development LLC (PPD) 181
PRA Health Sciences Inc. 182
Quanticate Ltd 183
Samsung Bioepis Co. Ltd 184
SGS SA (SGS Life Sciences) 185
Syneos Health Inc. 186
WuXi AppTec Inc. 187
9 Investing in Global Market: Risk Assessment and Management 188
9.1 Risk Evaluation of Global Market 188
9.2 Critical Success Factors (CSFs) 191
Related Reports and Products 194
Key Players (this may not be a complete list and extra companies can be added upon request):
Company Profiles of CMO:
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH
8.3.2 Company Profiles of CRO:
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
ICON Plc
IQVIA Holdings Inc.
LSK Global Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.
Ěý
Ěý
*If Applicable.
